Key result
Postnatal propranolol promotes progressive regression of septal hypertrophy and LVOTO in neonatal hypertrophic cardiomyopathy.
Why the study?
Does postnatal propranolol therapy improve echocardiographic parameters in neonates with prenatally diagnosed hypertrophic cardiomyopathy?
Case Report (n=1)
No
Does postnatal propranolol therapy improve echocardiographic parameters in neonates with prenatally diagnosed hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Early prenatal echocardiographic diagnosis of fetal hypertrophic cardiomyopathy enables timely postnatal monitoring and initiation of beta-blocker therapy, potentially reversing functional obstruction and structural hypertrophy.
A 34-year-old pregnant woman at 23 weeks of gestation was referred for fetal cardiomegaly, later diagnosed as fetal hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. The neonate, delivered vaginally at 39 weeks, was treated with propranolol and has shown favorable progress under regular follow-up.
No takes yet. Share an insight, caveat, or question.
Golbabaei et al. (2025) conducted a case report in Fetal hypertrophic cardiomyopathy (n=1). Propranolol was evaluated on Echocardiographic resolution of septal hypertrophy and left ventricular outflow tract obstruction. Postnatal propranolol therapy resulted in progressive regression of septal hypertrophy and left ventricular outflow tract obstruction in a neonate with fetal hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: